Allakos Inc

NASDAQ ALLK

Data sourced from

and

Download Data

Allakos Inc Capital Stock Change 1 year YoY Change (%) for the year ending December 31, 2023: -99.30%

Allakos Inc Capital Stock Change 1 year YoY Change (%) is -99.30% for the year ending December 31, 2023, a 0.70% change year over year. Capital Stock Change is the net change in the company's capital stock during a specific period, including the issuance or retirement of shares. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Allakos Inc Capital Stock Change for the year ending December 31, 2022 was USD 140.59 M, a 0.00% change year over year.
Allakos Inc Capital Stock Change for the year ending December 31, 2021 was USD 0.00, a -100.00% change year over year.
Allakos Inc Capital Stock Change for the year ending December 31, 2020 was USD 271.69 M, a -28.03% change year over year.
Allakos Inc Capital Stock Change for the year ending December 31, 2019 was USD 377.52 M, a 172.86% change year over year.

NASDAQ: ALLK

Allakos Inc

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive, Redwood City, CA, United States, 94065
Employees	131
Sector	Healthcare
Industry	Biotechnology

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key trends